Seeking Alpha

Raptor Pharmaceutical (RPTP) meets its primary endpoint in its Phase 3 clinical trial of delayed...

Raptor Pharmaceutical (RPTP) meets its primary endpoint in its Phase 3 clinical trial of delayed release Cysteamine for the treatment of nephropathic cystinosis. Shares, which had climbed as high as 5.5% earlier in the morning, are now +2%.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|